NCT03184870: A trial that was reported late by Bristol-Myers Squibb
This trial has reported, although it was 69 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03184870 |
|---|---|
| Title | A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 8, 2017 |
| Completion date | April 6, 2023 |
| Required reporting date | April 5, 2024, midnight |
| Actual reporting date | June 14, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 69 |